Biomea Fusion, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 3 rows, 3 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-04-20: Reporting owner Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Chen Bihua | Cormorant Global Healthcare Master Fund, LP; Form 4; Security Series A Convertible Preferred Stock; Transaction C Conversion of derivative security.
- 2021-04-19: Reporting owner Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Asset Management, LP; Form 4; Security Series A Convertible Preferred Stock; Transaction Holding.
- 2021-04-15: Reporting owner Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP | Chen Bihua; Form 3; Security Series A Convertible Preferred Stock; Transaction Holding.
BMEA insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-04-20 | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Chen Bihua | Cormorant Global Healthcare Master Fund, LP 10% Owner | 10% Owner | Director | 10% Owner | 4 | Series A Convertible Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | +2,270,872 0 owned after | no price filed | $16.79 | 2021-04-22 |
| 2021-04-19 holding as of filing | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Asset Management, LP 10% Owner | 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series A Convertible Preferred Stock Derivative · Indirect · See Footnotes | Holding | 2,270,872 owned after | no price filed | 2021-04-19 | |
| 2021-04-15 holding as of filing | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP | Chen Bihua 10% Owner | 10% Owner | 10% Owner | Director, 10% Owner | 3 | Series A Convertible Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2021-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |